title: Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.
abstract: BACKGROUND
  Treatment for chronic hepatitis B has improved drastically with the use of nucleot(s)ide analogues (NAs). However, NA therapy typically fails to eliminate Hepatitis B virus (HBV) completely, and it is difficult to discontinue these therapies. We previously demonstrated that NA therapy induced immature viral particles, including HBV RNA in sera of chronic hepatitis B patients. In the study reported here, we analyzed the association between HBV RNA titer and the recurrence rate of hepatitis after discontinuation of NA therapy.
  
  
  METHODS
  The study cohort comprised 36 patients who had discontinued NA therapy. Serum HBV DNA or DNA plus RNA levels were measured by real time PCR and statistical analyses were performed using clinical data and HBV markers.
  
  
  RESULTS
  At 24 weeks after discontinuation of NA therapy, HBV DNA rebound was observed in 19 of the 36 patients (52.8 %), and alanine aminotransferase (ALT) rebound was observed in 12 of 36 patients (33.3 %). Multivariate statistical analysis was used to identify factors predictive of HBV DNA rebound. The HBV DNA + RNA titer following 3 months of treatment was significantly associated with HBV DNA rebound [P = 0.043, odds ratio (OR) 9.474, 95 % confidence interval (CI) 1.069-83.957)]. Absence of hepatitis B e antigen (HBeAg) at the end of treatment was significantly associated with ALT rebound (P = 0.003, OR 13.500, 95 % CI 2.473-73.705). In HBeAg-positive patients, the HBV DNA + RNA titer after 3 months of treatment was marginally associated with ALT rebound (P = 0.050, OR 8.032, 95 % CI 0.997-64.683).
  
  
  CONCLUSIONS
  Monitoring of serum HBV DNA + RNA levels may be a useful method for predicting re-activation of chronic hepatitis B after discontinuation of NA therapy.
authors: Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
authors: Masataka
authors: M
authors: Tsuge
authors: Eisuke
authors: E
authors: Murakami
authors: Michio
authors: M
authors: Imamura
authors: Hiromi
authors: H
authors: Abe
authors: Daiki
authors: D
authors: Miki
authors: Nobuhiko
authors: N
authors: Hiraga
authors: Shoichi
authors: S
authors: Takahashi
authors: Hidenori
authors: H
authors: Ochi
authors: C
authors: C
authors: Nelson Hayes
authors: Hiroyuki
authors: H
authors: Ginba
authors: Kazuhiro
authors: K
authors: Matsuyama
authors: Hiroiku
authors: H
authors: Kawakami
authors: Kazuaki
authors: K
authors: Chayama
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood*; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood*; D060888:Real-Time Polymerase Chain Reaction; D012008:Recurrence
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D012367:RNA, Viral; D000410:Alanine Transaminase
references: Antivir Ther. 2010;15(2):177-84
references: 20386072
references: J Hepatol. 1998 Mar;28(3):510-3
references: 9551691
references: Antimicrob Agents Chemother. 2004 Sep;48(9):3498-507
references: 15328117
references: Hepatology. 2006 Jun;43(6):1385-91
references: 16729316
references: Alcohol Alcohol. 2000 May-Jun;35(3):296-301
references: 10869251
references: Genes Dev. 1987 Oct;1(8):773-82
references: 2828171
references: N Engl J Med. 2006 Mar 9;354(10):1011-20
references: 16525138
references: Hepatology. 1998 Jun;27(6):1711-6
references: 9620347
references: N Engl J Med. 2004 Mar 11;350(11):1118-29
references: 15014185
references: J Med Virol. 2009 Jan;81(1):27-33
references: 19031469
references: Lancet. 1993 Nov 27;342(8883):1340-4
references: 7694023
references: Clin Cancer Res. 2001 Jul;7(7):2005-15
references: 11448918
references: Gastroenterology. 2007 Apr;132(4):1574-85
references: 17408658
references: N Engl J Med. 2006 Mar 9;354(10):1001-10
references: 16525137
references: Gastroenterology. 2009 Nov;137(5):1593-608.e1-2
references: 19737565
references: J Clin Microbiol. 2002 Feb;40(2):439-45
references: 11825954
references: J Med Virol. 2007 Dec;79(12):1811-7
references: 17935165
references: J Med Virol. 2003 Sep;71(1):24-30
references: 12858405
references: J Hepatol. 2008 Jun;48(6):923-31
references: 18433925
references: Gastroenterology. 2002 Dec;123(6):1831-8
references: 12454840
references: J Virol. 1987 Jun;61(6):1808-13
references: 3033312
references: N Engl J Med. 1998 Jul 9;339(2):61-8
references: 9654535
references: Gut. 2005 Aug;54(8):1162-8
references: 16009689
references: Br Med Bull. 1990 Apr;46(2):329-53
references: 2198990
references: Intervirology. 2003;46(3):182-9
references: 12867757
references: Hepatology. 2007 Jul;46(1):254-65
references: 17596850
references: Semin Cancer Biol. 2000 Jun;10(3):211-31
references: 10936070
references: Hepatol Res. 2010 Feb;40(2):125-34
references: 19788696
references: J Hepatol. 2003;38 Suppl 1:S90-103
references: 12591188
references: Hepatology. 2011 Apr;53(4):1237-45
references: 21480328
references: Hepatology. 2007 May;45(5):1179-86
references: 17465002
references: Hepatol Res. 2012 Feb;42(2):139-49
references: 22103237
references: Antimicrob Agents Chemother. 2007 Mar;51(3):902-11
references: 17178796
references: Hepatol Res. 2010 Jan;40(1):1-7
references: 20156295